Troy Wilson, Kura Oncology CEO
December 9, 2024 09:16 PM ESTUpdated 06:27 AM
R&D

Ku­ra On­col­o­gy de­tails 'ag­gres­sive' ap­proach in first-line AML

Nicole DeFeudis

Editor

SAN DIEGO — As Ku­ra On­col­o­gy awaits key piv­otal da­ta in re­lapsed or re­frac­to­ry acute myeloid leukemia, the com­pa­ny is go­ing all in on com­bi­na­tions in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

IGM Bio­sciences’ au­toim­mune piv­ot lasts three months af­ter in­ter­im da­ta dis­ap­point

Ver­sant un­veils Light Horse with $62M and a part­ner­ship with No­var­tis

Shore­line cuts staff as its part­ner­ship with Gilead­'s Kite is now in flux

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Aio­los team re­unites with $411M for new biotech with obe­si­ty drugs from Chi­na

Af­ter lack­lus­ter 2024, bio­phar­ma in­dus­try prays stalled M&A will fi­nal­ly move in­to gear

A service from the Financial Times